DRTE Dendrite International (MM)

Dendrite International, Inc. (NASDAQ: DRTE) a leading provider of pharmaceutical industry solutions, today announced that it plans to release its fourth quarter earnings after the close of market on Thursday, February 15, 2007. A press release will be issued at 4 p.m. EST that day, followed by a conference call at 5 p.m. EST. Information on how to access a live simulcast or replay of the call via webcast or telephone can be found by visiting the Investors' Highlights section of www.dendrite.com. About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company�s clients are located in more than 50 countries, and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. FORWARD LOOKING INFORMATION: This document contains forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. All of our "outlook" information constitutes forward looking statements. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks associated with estimating and planning for (i) revenues based on customer decisions and (ii)unanticipated and unplanned for events over a 12 month or more period; risks which may result from our dependence on the pharmaceutical industry; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers, including the risk associated with our largest customer's plans to transition a significant portion of its U.S. sales force effectiveness services needs; fluctuations in quarterly revenues due to lengthy sales and implementation cycles; the success of our Operational Effectiveness program and ability to achieve the cost savings in the amounts and time periods expected and budgeted; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; risks associated with foreign currency fluctuations as they affect our non-U.S. operations; risks associated with our expanded international operations and our ability to adopt and respond successfully to the unique risks involved in our non-U.S. operations; any difference between estimated and actual stock option expense; and risks associated with reviewing and considering strategic options, as previously announced, and with any transaction occurring or being consummated at any subsequent time. Other important factors that should be reviewed and carefully considered are included in the Company's 10-K under "Factors That May Affect Future Results" and its 10-Qs and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating, and does not plan or undertake to update, any such forward-looking statements to reflect actual results, changes in expectations or assumptions or other changes affecting such forward-looking statements, even if such results or changes make it clear that any such projected results will not be achieved. Any outlook and other forward-looking information is as of the date of this release only. At any such time in the future as the Company may provide revenue, earnings and other outlook information, prior related outlook should no longer be considered current. Our outlook and other forward-looking information do not take into account or reflect any possible future acquisitions, dispositions or similar transactions which may occur.